Botulinum toxin injection: A review of injection principles and protocols

International Braz J Urol

Volumn 33, Issue 2, 2007, Pages 132-141

  Rapp, David E ^a   Lucioni, Alvaro ^a   Bales, Gregory T ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Botulinum toxin; Detrusor overactive; Techniques

Indexed keywords

EID: 34249827604     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382007000200002     Document Type: Review

References (47)

1. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD: Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988; 139:919-22.
2. Kuo HC: Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology. 2003; 61: 550-4.
3. Zermann DH, Ishigooka M, Schubert J, Schmidt RA: Trigonum and bladder base injection of botulinum toxin A (BTX) in patients with severe urgency-frequency-syndrome refractory to conservative medical treatment and electrical stimulation. Neurourol Urodyn. 2001; 20: 412-3, Abstract.
4. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB: Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004; 64: 871-5
5. Kuo HC: Prostate botulinum A toxin injection - an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology. 2005; 65: 670-4.
6. Bagi P, Biering-Sorensen F: Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol. 2004; 38: 495-8.
7. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000; 164: 692-7.
8. Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al.: Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005; 174: 196-200.
9. Reitz A, Stohrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, et al.: European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004; 45: 510-5.
10. Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH: Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol. 2003; 44: 139-43.
11. Hajebrahimi S, Altaweel W, Cadoret J, Cohen E, Corcos J: Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. Can J Urol. 2005; 12: 2543-6.
12. Rajkumar GN, Small DR, Mustafa AW, Conn G: A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int. 2005; 96: 848-52.
13. Rapp DE, Lucioni A, Katz EE, O'Connor RC, Gerber GS, Bales GT: Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology. 2004; 63: 1071-5.
14. Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC: Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn. 2005; 24: 231-6.
15. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P: A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 2005; 174: 984-9.
16. Smith CP, Nishiguchi J, O'Leary M, Yoshimura N, Chancellor MB: Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology. 2005; 65: 37-41.
17. Rackley RR, Frenkl TL, Abdelmalak JB: Botulinum toxin: the promise of therapy for complex voiding dysfunction. Cont Urol. 2005; 38-52.
18. Grosse J, Kramer G, Tong TQT, Stoher M, Jakse G: Efficacy, dosage, and safety of Dysport English botulinum toxin A in sever neurogenic detrusor overactivity. Eur Urol. 2005; suppl. 4: Abst #405.
19. Kuo HC: Comparison of the therapeutic effects of suburothelial injection of botulinum A toxin at different doses for refractory detrusor overactivity. J Urol. 2006; 175: 113 (A347).
20. Ruffion A, Capelle O, Paparel P, Leriche B, Leriche A, Grise P: What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int. 2006; 97: 1030-4.
21. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO: Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999; 96: 3200-5.
22. Haferkamp A, Krengel U, Reitz A, Grosse J, Kramer G, Schumacher S, et al.: Are botulinum-A toxin injections into the detrusor of patients with neurogenic detrusor overactivity safe? Ultrastructural data of detrusor biopsies. Neurourol Urodyn. 2003; 22: 499-500.
23. Rapp DE, Turk KW, Bales GT, Cook SP: Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol. 2006; 175: 1138-42.
24. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB: Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol. 2004; 172: 1529-1532.
25. Sampaio FJ: Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. Int Braz J Urol. 2003; 29: 176-8.
26. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al.: Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005; 174: 977-82; discussion 982-3.
27. Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP: Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int. 2004; 45: 987-93.
28. Comperat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E: Histologic Features in the Urinary Bladder Wall Affected from Neurogenic Overactivity - A Comparison of Inflammation, Oedema and Fibrosis With and Without Injection of Botulinum Toxin Type A. Eur Urol. 2006; 50: 1058-64.
29. Del popolo G: Botulinum-A toxin in the treatment of detrusor hyperreflexia. Neururol Urodyn. 2001; 20: 522.
30. Wyndaele JJ, Van Dromme SA: Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 2002; 40: 599-600.
31. Kuo HC: Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology. 2005; 66: 94-8.
32. Smith CP, Chancellor MB: Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol. 2004; 171: 2128-37.
33. Kim HS, Hwang JH, Jeong ST, Lee YT, Lee PK, Suh YL, et al.: Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol. 2003; 45: 200-6.
34. Mahajan ST, Kenton K, Brubaker L: Cystoscopic intradetrusor botulinum A toxin injection for the treatment of detrusor overactivity incontinence. J Urol. 2006; 175: 539, Abst#1672.
35. Ray FR, Moore KH, Hansen MA, Barden JA: Loss of purinergic P2X receptor innervation in human detrusor and subepithelium from adults with sensory urgency. Cell Tissue Res. 2003; 314: 351-9.
36. Chuang YC, Fraser MO, Yu Y, Chancellor MB, de Groat WC, Yoshimura N: The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol. 2001; 165: 975-9.
37. Szallasi A, Fowler CJ: After a decade of intravesical vanilloid therapy: still more questions than answers. Lancet Neurol. 20021; 1: 167-72.
38. Vemulakonda VM, Somogyi GT, Kiss S, Salas NA, Boone TB, Smith CP: Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation. J Urol. 2005; 173: 621-4.
39. Lucioni A, Rapp DE, Gong EM, Fedunok P, Bales GT: Botulinum toxin type A injection for overactive bladder: trigone versus trigone-sparing injection. (In Press).
40. Grosse J, Kramer G, Stohrer M: Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol. 2005; 47: 653-9.
41. Doellgast GJ, Brown JE, Koufman JA, Hatheway CL: Sensitive assay for measurement of antibodies to Clostridium botulinum neurotoxins A, B, and E: use of hapten-labeled-antibody elution to isolate specific complexes. J Clin Microbiol. 1997; 35: 578-83.
42. Dykstra DD, Pryor J, Goldish G: Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: a case report. Arch Phys Med Rehabil. 2003; 84: 1399-400.
43. Dykstra D, Enriquez A, Valley M: Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct. 2003; 14: 424-6.
44. Reitz A, Schurch B: Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol. 2004; 171: 804; discussion 804-5.
45. Pistolesi D, Selli C, Rossi B, Stampacchia G: Botulinum toxin type B for type A resistant bladder spasticity. J Urol. 2004; 171: 802-3.
46. Ghei M, Maraj BH, Miller R, Nathan S, O'Sullivan C, Fowler CJ, et al.: Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol. 2005; 174: 1873-7.
47. Smaldone MC, Chancellor MB: Bladder or urethra injection of botulinum toxin type A: one institution's experience. Am J Urol Rev. 2005; 3: 422-426.